Forte Biosciences, Inc. (NASDAQ:FBRX – Get Free Report) CFO Antony A. Riley bought 22,514 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was purchased at an average cost of $5.55 per share, with a total value of $124,952.70. Following the completion of the transaction, the chief financial officer now owns 30,776 shares in the company, valued at $170,806.80. This represents a 272.50 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Forte Biosciences Stock Performance
Shares of NASDAQ FBRX opened at $16.00 on Monday. The stock’s 50-day moving average is $5.91 and its two-hundred day moving average is $2.73. Forte Biosciences, Inc. has a 1-year low of $4.11 and a 1-year high of $21.25.
Analysts Set New Price Targets
Separately, Chardan Capital increased their target price on shares of Forte Biosciences from $3.00 to $64.00 and gave the stock a “buy” rating in a report on Friday, November 15th.
About Forte Biosciences
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
Further Reading
- Five stocks we like better than Forte Biosciences
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Disney’s Magic Strategy: Reinventing the House of Mouse
- What is the Euro STOXX 50 Index?
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
